Scrip is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
| Other Publications: In Vivo | Medtech Insight | Pink Sheet | Rose Sheet |  |
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Printed By
Novartis AG's CAR-T cell therapy CTL019, set to be the first in this class to achieve a US FDA filing, might not be an immediate blockbuster owing to its tricky treatment logistics, small initial indication and a lack of physician and patient exposure, but it is still a game changer in immuno-oncology, says Dr. Oz Azam, Novartis's head of cell therapies.
| Table |
|---|
Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
